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4PREFACE
This study was carried out at the Gade Institute, University of Bergen between
1993 and 2005. While starting as a post graduate fellow supported by the
Norwegian Cancer Society, from 1996 I have held a position as consultant at the
Department of Pathology, Haukeland University Hospital. The first part of this
work was carried out in collaboration with Professor Flora Hartveit, who is hereby
thanked for introducing me to research. During these years, diagnostic pathology
has advanced from a strict morphological fundament to a more versatile existence
in the sphere that lies between morphology and cell biology. This is particularly
true since the introduction of immunological and molecular biological techniques.
Professor Ole Didrik Lærum urged me to enter this exciting field between basic
research and clinical pathology. The inspiration I gained from working in the
“Lærum group”, with its assorted approaches to cancer research and noble
achievements, cannot be overestimated. I am deeply grateful to Professor Lærum
for his skillful supervision, optimism and encouragement.
Professor Anders Molven introduced me to quantitative real-time PCR
and guided me through many difficulties. He has also been an important discussion
partner, and is sincerely thanked for his significant contribution.
Thanks are also extended to all my coworkers and technicians in the
laboratory. Prosector Nils-Petter Aardal, Professor Einar Svendsen, Professor Inge
Morild and Professor Karl Henning Kalland have in turn been chairmen of the
Department and thanked for the excellent working facilities.
Finally, my thanks to my wife, Anne, and daughter, Hanne, who have
borne with me during this long and somewhat winding road.
Bjørn I. Bertelsen
5ABBREVIATIONS USED
bp: base pairs
CIN: cervical intraepithelial neoplasia
CGH: comparative genomic hybridization
CDK: cyclin dependent kinase
CT: threshold cycle
DNA: deoxyribonucleic acid
GCK: glucokinase gene
E6-AP: E6-associated protein
ECM: extracellular matrix
EGF: epidermal growth factor
EMT: epithelial-mesenchymal transition
ERK: extracellular signal-regulated kinase
eNOS:  nitric oxide synthase
FHIT: fragile histidine triad tumor suppressor
FIGO: Fédération International de Gynécologie et Obstétrique
/International Federation of Gynecology
FOXO: the FOXO family of transcription factors
HGF: hepatocyte growth factor
HIF1α: hypoxia-inducible factor alpha
HPV: human papillomavirus
HRG: histidine-rich glycoprotein
IL-8: interleukin 8
IKK: IĸB kinase
ILK: integrin-linked kinase
JOE: 6-carboxy-dichlorodimethoxyfluorescein
LSIL: low-grade squamous intraepithelial lesion
LEEP: loop electrosurgical excision procedures
HSIL: high-grade squamous intraepithelial lesion
HSV-2: Herpes Simplex Virus type 2
IGF-1R: insulin-like growth factor 1 receptor
6ISH: in situ hybridization
NF-ĸB : nuclear factor ĸB
PDGF: platelet derived growth factor
PDK-1: 3-phosphoinositide-dependent protein kinase-1
PDK-2: 3-phosphoinositide-dependent protein kinase-2
PH: pleckstrin homology
PI3K: phosphatidylinositol 3-kinase
PIP3: phosphatidylinositol 3,4,5 trisphosphate
PCR: polymerase chain reaction
PTEN: phosphatase and tensin homolog deleted on chromosome 10
Rb: retinoblastoma tumor suppressor protein
RFLP: restriction fragment length polymorphism
RTK: receptor tyrosine kinase
RT-PCR: reverse transcription-polymerase chain reaction
SNOP: systematized nomenclature of pathology
SNOMED:  systematized nomenclature of medicine
SIL: squamous intraepithelial lesion
TAMRA: 6-carboxy-tetramethylrhodamine
Taq: Thermus aquaticus
Tm: melting temperature
TOR: target of rapamycin
TSC2: tuberous sclerosis complex 2
VEGF: vascular endothelial growth factor
VEGFR-1: vascular endothelial growth factor receptor 1
VEGFR-2: vascular endothelial growth factor receptor 2
7BACKGROUND
During the course of my studies of cervical neoplasia, new insights have radically
changed the understanding of this cancer type.  The general introduction of this
thesis will therefore start with an overview of the current knowledge of the disease,
including aspects of its fundamental biology, practical clinicopathological
considerations, and screening.  Finally, I will give a survey of biobanks and how
old, archival pathology material  can yield new insights into the biology of cervical
neoplasia.
The cervical cancer load
Uterine cervical cancer accounted for an estimated 274,000 deaths world-wide in
20021.  With nearly 500,000 new cases per year, it is the second most common
cancer in women world-wide1.  It is one of  the leading causes of cancer-related
deaths in young women2.  The disease incidence shows marked geographical
variation.  An estimated 83% of new cases now occur in the developing countries,
where it represents 15% of new cancers in women1.  In contrast, cervical neoplasia
accounts for only 3.6% of new female cancers in the developed world1.  The low
incidence rate in developed countries is a rather new phenomenon, as the incidence
in most of Europe, North America, Australia and New Zealand before the
introduction of cytological screening in the 1960s and ‘70s, was similar to that in
the developing countries today3,4.  In Norway, 270 women were diagnosed with
cervical cancer in 2004 and there are about 100 deaths every year5.  The age-
specific incidence maximum was 21 per 100,000 women at age 45-49 years5.
Morphology and classification
Cervical cancers arise in the transformation zone, i.e. the zone between the original
and current squamocolumnar junctions (Figure 1)6.   Squamous cell carcinomas
make up about 80% of cervical cancers, adenocarcinomas make up about 15%,
8while the rest include some rare carcinoma types and neuroendocrine tumors7,8.
Figure 1.  The cervical transformation zone at different physiological stages.
From Wells 9.
Cervical squamous cell carcinomas originate from intraepithelial precursor
lesions, cervical intraepithelial neoplasia (CIN) (Figure 2),  characterized by a
disordered morphology of the squamous epithelium with proliferation of primitive
cells beginning in the basal portions of the epithelium6,10.  These so-called
undifferentiated neoplastic cells have enlarged, pleomorphic, hyperchromatic
nuclei and high mitotic counts6,11.  Abnormal mitotic figures are sometimes found
in the undifferentiated neoplastic cells and are indicative of an aneuploid cell
population12.  CIN is a flat lesion located in the transformation zone, and seldom
visible to the naked eye.  Colposcopic examination may reveal areas of abnormal
epithelium.  A more specific diagnosis can be reached following microscopy of a
cytological smear or a biopsy.  The division into CIN grades 1-3 was meant to
reflect a biological continuum of risk for the development of carcinoma6.  In
cervical intraepithelial neoplasia grade 1 (CIN 1) the undifferentiated neoplastic
cells are found in the basal one-third of the epithelium, in CIN 2 they are present in
the basal two-thirds of the epithelium, while in CIN 3 the upper one-third of the
epithelium is also affected6,11 (Figure 2).  In CIN 1 and 2, and sometimes in CIN 3,
differentiating pre-neoplastic cells are present in the epithelium superficially to the
undifferentiated neoplastic cells8.  The increased nucleo-cytoplasmic ratio in the
exfoliated neoplastic cells is the clue to the cytological diagnosis of CIN.  In CIN 1
the nucleus occupies up to one half of the total area of the cytoplasm, in CIN 2 it
occupies between one half and two thirds of the cytoplasmic area, and in CIN 3 it
9occupies more than two thirds of the cytoplasmic area11.  In all three lesions, the
nuclei are pleomorphic, hyperchromatic and irregular .
Figure 2.  Pre-invasive squamous lesions in the uterine cervix.   From Wright
et al.13.
The concept of a stepwise development of cervical squamous cell carcinoma
was introduced nearly a century ago14.  A variety of terms have been used for the
pre-invasive lesions, i.e. atypical squamous epithelium, incipient carcinoma,
carcinoma in situ, atypical hyperplasia, dysplasia, CIN and squamous
intraepithelial lesion (SIL)15-21.  When attention was drawn to human
papillomavirus and its possible relation to cervical neoplasia, a variety of terms
describing the association between viral changes and pre-invasive lesions were
suggested22-24.  Later, the Bethesda system intended for use in cytology, introduced
terms for undetermined specimens, i.e., ‘atypical squamous cells of undetermined
significance’ (ASCUS) for abnormal squamous cells that may or may not be pre-
malignant or malignant and ‘atypical squamous cells, cannot exclude high-grade
squamous intraepithelial lesion’ (ASC-H) for those cases where a high-grade lesion
is difficult to exclude.  Furthermore, the Bethesda system lumped human papilloma
virus infection and CIN 1 together as a low-grade squamous intraepithelial lesion
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(LSIL) and merged CIN 2 and 3 as high-grade squamous intraepithelial lesions
(HSIL)20,21.  However, the CIN-classification is still regarded as the system best
suited for histopathology25,26.  The suggested modified terms “low-grade-“ and
“high-grade CIN” for CIN 1 and CIN 2-3 respectively, would bring it closer to the
Bethesda system27,28.  In Norway the CIN classification prevails in histopathology,
while the Bethesda system recently has been taken up in cytology29.
Cervical carcinogenesis
A modern definition of a neoplastic cell is one that has clonally expanded as a
result of somatic mutations30.  Neoplastic development may be viewed as an
evolutionary process where the cells acquire genetic lesions selectively
advantageous to their survival and proliferation31. CIN 3 and invasive cervical
carcinomas are monoclonal, and it seems that the pre-invasive lesions develop into
a monoclonal lesion during the progression from CIN 1 to CIN 332-35.  Self-
sufficiency in growth signals, insensitivity to antigrowth signals, evasion of
apoptosis, limitless replicative potential, sustained angiogenesis, tissue invasion
and metastasis have been postulated as hallmark alterations in cell physiology
shared by most human cancers36.  Many of these changes may be incited by viruses
that have evolved mechanisms to modulate cellular signaling pathways to
reprogram host cells to support the viral life cycles or modulate host defense
responses.
Human papillomavirus infection
A role for human papillomavirus (HPV) in cervical neoplasia was suggested by
Harald zur Hausen in the early 1970’s37.  Work in his laboratory resulted in the
identification of HPV DNA in condyloma accuminatum and cervical cancer
tissues38-40.  It is now generally accepted that human papillomavirus (HPV) play a
necessary, causative role in cervical carcinogenesis41-44.  Besides, HPV is a
probable causative factor in a proportion of anal, perianal, vulvar, penile,
oropharyngeal and skin cancers45.
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HPV is a small non-enveloped virus that contains a double-stranded circular
DNA genome of about 8,000 basepairs46.  More than 200 different types of HPV
have been identified on the basis of genomic differences46.  Specific subtypes of
HPV that carry a considerable risk of causing malignant progression in the uterine
cervix are termed high-risk HPV (Table 1)2,43.  HPV 16 is the most commonly
occurring subtype in cervical neoplasia43, however, HPV 18 is associated with
more advanced cervical neoplasia than HPV 1647.  The virus infects the basal cells
of the epithelium, probably binding to the α6β4-integrin48.  HPV DNA is
maintained at a low copy number in the nuclei of the differentiating epithelial cells
as they move toward the epithelial surface, while replication to a high copy number
with production of progeny virus occurs in terminally differentiating cells46.
Viral feature HPV types
Carcinogenic 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, 82.
Probably carcinogenic 26, 53, 66.
Table 1.  HPV types considered carcinogenic or probably carcinogenic.
After Munoz et al.43.
The virus is transmitted through sexual contact49-51.  Genital HPV infections
are abundant, and infection with more than one HPV type is not uncommon52-58.
Sexual activity at early age, large number of sexual contacts, poor hygiene,
uncircumcised male partners and compromized immune defense are factors that
increase the risk for genital HPV infection in women26,59-65.  The prevalence of
high-risk HPV has been found to peak in the youngest women, decline in middle
aged women, and then increase slightly in older women66.  HPV DNA has been
detected by Southern blot in 25-40% of adolescents in a single screening visit67.
Estimates of life-time risk based on cytological screening showed that up to 79%
of Finnish females would contract at least one HPV infection between ages 20 and
79 years52.  Even if most infections clear without sequelae in 1-2 years, persistence
of the infection may eventually result in integration of  HPV DNA into the host
cell genome, an event considered a prerequisite for malignant development46,68-71.
The morphological changes of HPV-infection are commonly found in
association with CIN and have been described in detail11,23,72-75.  The most
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consistent of the so-called epithelial cytopathic effects are koilocytosis,
dyskeratosis and multinucleation11.  Histologically, a flat lesion is usually seen (flat
condyloma/condyloma planae), but it may be elevated (condyloma accuminatum)
or endophytic (inverted)11,24.
HPV oncoproteins
HPV integration sites are randomly distributed over the whole human genome with
a clear predilection for fragile genomic sites76.  While most of the open reading
frames of the integrated viral DNA are lost or interrupted, the high-risk HPV
proteins E6 and E7 continue to be expressed, accounting for the transforming
ability of the virus45,68,77.  E6 binds and degrades the tumor suppressor p5378,79,
while E7 disrupts the function of the retinoblastoma (Rb) family of cell cycle
regulators80.  Even if the functions of each viral protein have been thoroughly
examined in isolation, these analyses do not accurately represent the in vivo
scenario in cases of cervical cancer, where both E6 and E7 are always present45.
E6 and E7 interact with numerous cellular proteins resulting in a diversity of
biological effects45,46,81.  In many cases the relevance of these interactions still
remains to be determined46.   However, it is clear that high-risk HPV E6 and E7 are
both individually able to immortalize many different human cells, even if their
cooperative action results in a considerably increased immortalization efficiency81-
83
.  The E6 and E7 genes of non-carcinogenic HPV have only weak immortalizing
activity in human epithelial cells84.  
E6 has mutagenic and antiapoptotic effects that are key elements in tumor
progression45.  It binds the cellular tumor suppressor protein p53, indirectly
through a complex formed with the E6-associated protein (E6-AP)46.  This results
in the degradation of p53 by ubiquitin-dependent proteolysis79,85.  Because of the
p53 degradation, E6 overrides the G1/S checkpoint control in DNA-damaged cells
and exerts a mutagenic effect45.  E6 also has antiapoptotic effects through the
elimination of p53 and degradation of the proapoptotic protein Bak, a member of
the Bcl-2 family45.  Besides, it has recently been demonstrated that E6-mediated
inactivation of the Bax-dependent proapoptotic pathway is crucial for protection of
HPV-positive cancer cells from apoptotic cell death86.  Upregulation of c-IAP2
gene expression by both E6 and E7 has also been reported and seems to confer
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resistance to apoptosis contributing to sustained growth in high-risk HPV positive
cancer cells87.  Shortening of the chromosomal telomeric termini with each round
of DNA replication autonomously restricts the number of cell divisions in a normal
cell, while in many malignant tumors this effect is prevented by the expression of
telomerase46.  In high-risk HPV induced lesions, E6 stimulates expression of host
cell telomerase, contributing further to cell immortalization88,89.
E7 has cell cycle driving effects.  It binds the retinoblastoma-susceptibility
gene product pRb as well as some of its family members, including p107 and p130,
regulators of the progression of cells from the G1-phase into the S-phase of the cell
cycle80,90,91.  This results in phosphorylation and degradation of pRb and its family
members and to a release of the E2F transcription factor that activates expression
of several growth promoting genes45.  This ability of E7 to destabilize pRb and
related proteins with a resultant truncation of an important mechanism in the
control of cell proliferation seems to be critical for cellular transformation46.
Another essential growth stimulatory effect of E7 is the inactivation of the cyclin-
dependent kinase inhibitors p21CIP1 and p27KIP1, thus bypassing cell cycle arrest
during keratinocyte differentiation46.   The newly identified cellular protein
retinoblastoma protein-associated factor, p600, that regulates cellular pathways
contributing to anchorage-independent growth, binds to E7 and seems to contribute
to the transforming properties of E792.
The viral load and E6/E7 expression level appear to be important
determinants for neoplastic development.  Recently, a dose-response relationship
between increasing high-risk HPV viral load and risk of pre-invasive lesions was
suggested93.   Likewise, higher HPV DNA copy numbers per cell are associated
with increasing risk of development of adenocarcinoma of the cervix94.  Further,
the HPV E6/E7 expression level has been found to play a key role in progression
of invasive carcinoma of the cervix95. A suggested scheme of high-risk HPV-
mediated carcinogenesis is shown in Figure 3.
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Figure 3. A possible scheme of high-risk HPV-mediated carcinogenesis.
After zur Hausen45.
Genetic aberrations
Chromosomal instability is an early event in cervical carcinogenesis96.
Collectively, the expression of E6 and E7 gives rise to mitotic defects and
numerical and structural chromosome instability through the induction of
centrosome abnormalities, thus enabling the cells to acquire genetic alterations
necessary for survival and clonal expansion97-102.  However, the alternative view
that chromosomal instability and aneuploidization precede integration of high-risk
HPV genomes are supported by one study of biopsies from CIN and carcinomas103.
Cervical carcinomas show a recurrent pattern of cytogenetic changes where
chromosomal gains generally are more common than losses104,105.  Gains of
chromosomal regions 1q, 3q, 5p and 8q and loss of 2q, 3p, 4p, 4q, 6q, 11q, 13q and
18q are the most frequent changes104,105.  The most common deletion is that of
chromosome 3p with loss of 3p14.2 encoding the tumor suppressor fragile histidine
triad (FHIT) identified in 40% of cervical cancers104,105.  Gain of the long arm of
chromosome 3 is the single most frequent change overall97,105-109.  The same
aberration has been demonstrated in HPV-transfected keratinocytes, pre-malignant
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cervical precursor lesions and cervical cancer cell lines97,106,110-112.  By comparative
genomic hybridization (CGH), the areas of gain have been refined to parts of
chromosomal bands 3q24-2998,107-109.  PIK3CA at 3q26.3 is a candidate oncogene
in this region113,114.
The PI3K-AKT pathway
One of the major intracellular signaling pathways leading to cell growth involves
phosphatidylinositol 3-kinase (PI3K)(Figure 4).  This kinase principally
phosphorylates inositol phospholipids.  It can be activated by receptor tyrosine
kinases, as well as by many other types of cell surface receptors.  PI3K generates
inositol phospholipids that trigger phosphorylation of AKT, an effector of
potentially tumor-driving signals113.  PTEN reverses the action of PI3K115.
Deregulation of PI3K-AKT signaling occurs in many types of cancers, and may
result from PTEN inactivation or overexpression of PI3K113,115-118.
PI3K is a heterodimer with a regulatory subunit, p85α, and a catalytic
subunit, p110α118.  Several isoforms and subgroups of PI3K exist, however, only
class IA PI3K is involved in carcinogenesis113,118, and the one dealt with here.
p110α is encoded by the above-mentioned gene PIK3CA located at 3q26.3113.
Different mechanisms of PI3K activation exist.  The regulatory subunit p85α
is a direct substrate of receptor tyrosine kinases and G-protein-coupled receptors,
and triggers activation of the catalytic subunit p110α113,114.  Activation of p110α
can also occur through the Ras protooncogene, possibly acting in concert with
p85α114,119.  Upon activation, class IA PI3K is recruited to the inner surface of the
plasma membrane, where it catalyzes the transfer of phosphate from ATP to the D-
3 position of the inositol ring of membrane-localized phosphoinositides, thereby
generating 3’-phosphorylated phosphoinositides, most notably phosphatidylinositol
3,4,5 trisphosphate (PIP3)114,119.  PIP3 interacts with the pleckstrin homology
domain of AKT, and as a consequence AKT is translocated from the cytoplasm to
the inner leaflet of the plasma membrane119.
AKT (or protein kinase B) is a Ser/Thr kinase that has three isoforms, AKT1,
AKT2  and AKT3.  It is activated by ligand-stimulated growth-factor-receptor
signaling in a PI3K-dependent manner.  AKT is thereby phosphorylated at
threonine 308 and serine 473 by two kinases localized at the inner surface of the
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plasma membrane, 3-phosphoinositide-dependent protein kinase-1 (PDK-1) and
the still elusive 3-phosphoinositide-dependent protein kinase-2 (PDK-2)113.
Thr308 phosporylation by PDK-1 is sufficient for AKT activation120, however,
maximal activation of AKT requires additional Ser473 phosphorylation121.  The
lipid phosphatase PTEN (phosphatase and tensin homolog deleted on chromosome
10) negatively regulates AKT by dephosphorylating PIP3 at the 3-position122.
PTEN, traditionally considered a strictly cytoplasmic protein, also shuttles to the
nuclear compartment, where its role is still elusive123.
Figure 4.   A core scheme of the PI3K-AKT signaling network.  After Cully et
al.114.
PI3K-AKT deregulation in cancer
Deregulation of the PI3K-AKT pathway from one of a variety of causes has been
reported in large number of cancers124,125.  Constitutive activation of PI3K resulting
from PIK3CA mutations has been found in a proportion of cancers of the colon,
brain, stomach, breast and lung117,126 and from mutation in the gene coding for
p85α in some colonic and ovarian carcinomas127.  Further, PIK3CA amplification
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has been reported in cancers of the ovaries, uterine cervix, head and neck, stomach
and brain128-132.
Germline mutations in PTEN are present in two rare autosomal dominant
syndromes with the common feature of the development of hamartomas in various
organs and increased cancer risk, namely Cowden syndrome and Bannayan-Riley-
Ruvalcaba syndrome122.  Somatic point mutations in PTEN occur in many sporadic
tumors in which the other copy of the gene is mostly inactivated by deletions, for
instance glioblastoma, melanoma and carcinomas of the breast, prostate,
endometrium, kidney and colon133-140.  The germline mutations associated with the
syndromes and the somatic mutations in tumors are clustered in exon 5 encoding
the catalytic domain of PTEN139.  PTEN point mutations usually result in
inactivation of the PTEN-protein141.  PTEN down-regulation may also result from
promoter hypermethylation, as reported for endometrial and colorectal cancers142-
144
.
Some cancers and cancer cell lines of the stomach, brain, ovaries, pancreas
and breast display AKT amplification132,145-147.  Furthermore, overexpression of
AKT has been reported in colorectal and hepatocellular carcinomas148,149.
Upstream changes that activate PI3K occur in some tumors.  One example is
overexpression of the receptor tyrosine kinase gene ERBB2 (HER2/NEU) in breast
cancer, which results in constitutive activation of PI3K-AKT and may contribute to
tumor aggressiveness by enhancing cell survival150,151.
Important substrates of the AKT kinase are p27KIP1, the forkhead box
transcription factors of the FOXO class, glycogen synthase kinase 3, serum-and
glucocorticoid-induced kinase 1 and tuberous sclerosis complex 2 (TSC2)114.
Crosstalk between the PI3K-AKT pathway and other signaling pathways can
contribute to tumorigenesis through synergistic effects, in particular the Ras
pathway and the p53 pathway114 (Figure 4).  Phosphorylation of TSC2 by AKT
results in the activation of TOR (target of rapamycin)114.  The carcinogenesis-
driving effects of TOR remain elusive114.  TOR can form two different complexes,
one of which, the rapamycin-insensitive TOR complex, can also phosphorylate and
activate AKT114.
Recent reports have introduced additional mechanisms of PI3K-AKT
activation which need further elucidation.  Several viral proteins can interfere with
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the PI3K-AKT pathway, and it is of special note that HPV E7 have been shown to
amplify AKT signaling by inhibition of AKT dephosphorylation152,153.
Effects of PI3K-AKT deregulation
Deregulation of the PI3K-AKT pathway may stimulate several alterations in cell
physiology that are hallmarks of cancer development, i.e. evasion of apoptosis,
limitless cell proliferation, sustained angiogenesis, invasion and metastasis36.
PI3K-AKT also affects other cellular changes that may promote malignant
development like epithelial-mesenchymal transition, cell matrix interactions and
anoikis resistance.
Activation of PI3K-AKT protects cells from apoptosis by coordinating
programs that directly inhibit apoptotic effectors and suppress transcription of pro-
apoptotic genes, as recently reviewed154.  AKT is the principal mediator by
preventing the release of cytochrome c from the mitochondria, and by inactivation
of the pro-apoptotic factor BAD and the cell death effector Caspase 9.  Also, by
repressing the activity of the FOXO class transcription factors and activating IĸB
kinase, AKT blocks activation of several pro-apoptotic proteins  and brings about
nuclear translocation of the pro-survival transcription factor NF-ĸB,118.  AKT can
affect the pro-apoptotic tumor suppressor p53 by phosphorylation of MDM-2,
which speeds up translocation of MDM-2 to the nucleus, thus increasing p53
degradation154.
Epithelial cells die in an apoptotic process called anoikis if they lose
contact with the matrix155.  Anoikis resistance is fundamental in malignant
transformation of epithelial cells156, and has been demonstrated to be brought about
by PI3K-AKT mediated caspase suppression induced by expression of the TrkB
tyrosine kinase receptor157.
AKT stimulates cell cycle progression at the G1/S transition by aiding in
activation  of cyclin dependent kinases (CDKs).  Firstly, it blocks the degradation
of Cyclin D1 through inactivation of its regulating kinase, glycogen synthase
kinase-3β158.  Furthermore, AKT indirectly restrains expression of CDK inhibitors,
such as p27KIP1 and p21CIP1 125,159.
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Development of new vascular channels is necessary to nourish a growing
number of tumor cells.  The PI3K-AKT pathway plays an essential role in the
induction of angiogenic cytokine release (most notably vascular endothelial growth
factor and interleukin 8) as a response to hypoxia and growth factor stimulation160-
164
.  Furthermore, the PI3K-AKT pathway is central in the endothelial cell response
as it mediates endothelial cell survival and migration through several effectors165-
167
.  It may be of relevance in this context that colposcopic evaluation of the cervix
is based partly on the visualization of vascular changes in the mucosa.
Activating mutations of PI3K have been shown to boost cancer cell
invasivenes117.  PI3K-AKT has a central role in the interaction between neoplastic
cells and extracellular matrix (ECM) during tumor invasion.  It regulates both the
urokinase plasminogen activator-1 which degrades plasminogen in the ECM and
matrix metalloproteinase 9 that degrades collagen IV168-170, and through mTOR it
plays a central role in upregulation and activation of matrix metalloproteinase 2171.
Invasion and metastasis seem to be dependent on the acquisition by the
neoplastic cell of mesenchymal, fibroblast-like properties with reduced
intercellular adhesion and increased motility, a process called epithelial-
mesenchymal transition (EMT)172.  PI3K-AKT has been demonstrated to induce
EMT in various cancer cell types, including HPV-infected cervical cancer cell
lines173,174.
Integrins are the major family of cell surface receptors that mediate
attachment to the ECM, an essential process for cancer cell motility.  PI3K-AKT
regulates integrin-dependent cell motility by modulating integrin responses175.  In
addition PI3K may regulate cell movement through modulation of a variety of
other effectors controlling formation and extension of cellular actin protrusions
(i.e. lamellipodia and filopodia)176,177 .
Even if deregulation of the PI3K-AKT pathway usually seems to promote
cancer development,  paradoxical effects of AKT have been reported.  It appears
that hyperactivation of AKT in some instances may suppress cell motility and
invasion.  Thus, in one report breast cancer cell migration and invasion was shown
to be blocked by AKT activation178.  In addition, overexpression of activated myr-
Akt1 in human breast cancer cells has recently been found to reduce motility and
invasion179 .  Furthermore, the three AKT isoforms do not always seem to share the
same cellular functions, as evidence for AKT isoform-specificity in regulating
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growth-factor stimulated phenotypes in breast epithelial cells has been provided180.
In that study AKT1 downregulation seemed to promote EMT and cell migration,
while AKT2 downregulation reversed hyperproliferation and anti-apoptotic
activities180.
Host factors
As high-risk HPV infections give rise to cervical carcinoma only in a small
fraction of women and usually after a latency period of 10-15 years, additional host
factors are probably necessary for development of the malignant phenotype45,181,182.
Experimental studies show that neither the individual HPV oncogenes nor their
cooperative action are sufficient to convert normal cells into a malignant state45.
A genetic predisposition in cervical neoplasia was first demonstrated by a
study utilizing data from the Swedish Cancer Registry183.  The host-cell gene
alterations responsible for this predisposition are at present under investigation.
Single nucleotide polymorphisms in p53 may play a role, but have not been proved
important in the development of human papillomavirus-associated cancer184-188.
Claims that polymorphisms in the Fas promoter, Fas gene, Fas ligand and the
genes coding for matrix metalloproteinase-1 (MMP1) and TNF-α are relevant for
genetic predisposition for cervical cancer, need further exploration 105.
Changes in host genes involved in control of HPV oncogene expression
would be of special importance45.  While the existence of such genes is likely, the
molecular mechanisms of a host-mediated antagonism of the viral oncoproteins is
poorly understood45.  A negative interference of cyclin-dependent kinase inhibitors
with the HPV oncoproteins has been suspected2.  Blocking of HPV DNA
transcription through modifications of the transcription factor AP1 has been
demonstrated, and interruption of this effect has been shown to occur during
malignant transformation189.  Host factors may also directly affect the persisting
viral DNA, for instance by upregulation of viral gene transcription, modification of
the viral promoter region or by amplification of the viral genomes2.
The immune system is a key player in host control of HPV infections, and a
large proportion of infected women clear the infection by immunological
mechanisms2.  Still, low copy number high-risk HPV infections can persist in some
women for decades without causing clinically overt lesions46, as recently also
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demonstrated for elderly women190.  Spontaneous regression of HPV lesions
appears to depend on either naturally acquired or iatrogenically related stimulation
of HPV type-specific immunity191.  While the humoral antibody response to HPV
particles may be important in preventing infection, the local events surrounding
regression of HPV lesions are primarily associated with specific cell-mediated
immunity191.  Malfunction of the cellular immune response following for instance
HIV-induced depletion or iatrogenic inhibition of CD4-lymphocyte activity,
enhances the progression of HPV-induced cervical lesions to malignancy192.   T-
cells with specificity against E7 seem to participate in the control of HPV, and may
be associated with resolution of pre-invasive lesions, while carcinomas do not
seem to be eliminated193,194.
HLA class II-mediated immune response to HPV may control the viral
load195.  It may therefore not be surprising that carriers of certain HLA class II
alleles seem to be more prone to HPV infection and cervical carcinoma, while
other HLA class II alleles appear to have a protective effect196-202.  In a recent study
patients with HLA*201 who had CIN 2 or 3 caused by HPV types other than 16
had a significantly lower regression rate than other patients203.  A meta–analysis
indicates that a HLA-restricted HPV-specific immune response plays a key role in
controlling disease outcome202.
Cigarette smoking has been associated with an increased risk for cervical
neoplasia204-207.  A recent meta-analysis of 23 epidemiological studies with
stratification for age, number of sexual partners, age at first intercourse, oral
contraceptive use and parity concluded that current smokers have a relative risk of
1.60 for cervical squamous cell carcinoma as compared to never smokers, while no
association between smoking and adenocarcinoma was found208.  Although high
levels of nitroso-compounds derived from tobacco smoke have been detected in the
cervical mucus of smokers209,210, it remains to be settled whether these mutagenic
components take part in the development of cervical malignancy211.  Loss of FHIT
has recently been shown to be significantly more common in smokers than non-
smokers with cervical cancer, and may represent a molecular target in cigarette
smoking-associated cervical carcinogenesis.212.
Glucocorticoids and progesterone may hypothetically predispose to cervical
neoplastic development by activating HPV expression211.  Thus, indications of a
role for oral contraceptives in the causation of cervical neoplasia have been
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reported54,213-216.  A multicentric case-control study concluded that long-term use
of oral contraceptives could increase the risk of cervical carcinoma by up to four-
fold in women who are positive for cervical HPV DNA217.  However, findings on
the effect of oral contraceptive use are inconsistent between studies of different
designs207 and elevations of the physiologic levels of sex hormones do not seem to
contribute to the development of cervical neoplasia218.  Oral contraceptive use and
parity were not associated with increased risk of CIN 3 or cervical cancer in a
long-term prospective study219.
It has been speculated that poor nutritional status and low body weight may
be risk factors of cervical cancer, but this could not be confirmed in studies where
HPV status was also taken into account220.  However, as women with high levels of
folate are less likely to acquire genital infection with HPV, improved folate status
may to some extent protect against cervical cancer221.  An increased risk of CIN in
women with glomerulonephritis, independent of immunosuppressive treatment, has
also been reported222.
Infections other than HPV may be relevant for malignant development.
Chlamydia trachomatis serotype G has been associated with increased risk of
subsequent development of cervical squamous cell carcinoma223.  Furthermore,
Herpes Simplex Virus type 2 (HSV-2)  infection may act in conjunction with HPV
infection to increase the risk of cervical carcinoma224.
Cervical intraepithelial neoplasia
Occurrence
The prevalence of the causative viral factor is the key determinant for the
prevalence of cervical intraepithelial neoplasia.  Accordingly, sexual habits and
host factors rendering women susceptible to genital HPV infections,  will increase
the risk of developing CIN26,54,60,61,225-229.  In a screened population, the risk of CIN
has been demonstrated to increase with time since the previous cervical
smear230,231.
CIN has been reported in 1.4% to 4% of cervical smears in different
screening projects232-237.  The detection rate of CIN 3 has been reported from 0.2%
to 2.7%237,238.  An annual age-adjusted incidence rate of CIN of 233 per 100,000
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women has been estimated in a district with a high cervical cancer mortality239.
Results from screening projects indicate that CIN has the highest prevalence in
women between 20 and 40 years of age237,240,241, and not uncommon in
teenagers236,242.  In Sweden, the estimated age-specific incidence of carcinoma in
situ reached a maximum of 650 per 100,000 woman-years at the age of 30 years243.
The prevalence rates for CIN 1 and CIN 2 have been reported to fall with
age236,237,244-247, while higher rates of CIN 3 have been reported in older
women236,237,247.
Course
An established CIN lesion may regress, persist unchanged or progress to a more
severe lesion, i.e. a higher grade of CIN or invasive carcinoma.  Theoretically, the
natural course of  CIN may be influenced by removal of tissue for histological
examination or treatment.  Moreover, given the substantial interobserver variation
and low reproducibility of cervical cytologic and histologic interpretation, the
course of CIN is problematic to document248.  The conclusions from a major
review of studies dealing with the course of CIN10 are summarised in table 2.  A
large cohort study concluded that the majority of untreated CIN 1 regress to normal
within 2 years249.  Both CIN 1 and CIN 2 are more likely to regress than to
progress, while CIN 3 seems to regress in about one-third of cases10,249.  Recently,
regression of 28% of biopsy-confirmed CIN 2-3 was reported from a study were
100 women were followed prospectively for 15 weeks203.  Others have reported
regression of 32 and 50% of biopsy-proven CIN 2-3 during follow up for 12 weeks
and 12 months, respectively250,251.   Still, two other studies that followed women
with biopsy-proven CIN 3 for about 6 months found regression of 19 and 31% of
the lesions, respectively252,253.  Regression of CIN 3 may be age-dependent, as data
from some screening programs indicated that it occurred in 70-80% of younger
women and in 40-50% of older women254,255.  Regression of CIN 2 has been
reported as 19% or 27% during 6 months of observation252,253.
The progression rate from CIN 1 to CIN 3 or worse was in one large study
found to be only 1% per year, 5% within 5 years, 10% within 10 years249, while
Östör concluded that it eventually occurred in about 12% of the cases10.  However,
it is debated whether CIN 1 really is a precursor to CIN 2-36.  The Bethesda
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classification reflects the alternative view that CIN 1 should be regarded as the
manifestation of a productive HPV infection, and thus included in LSIL21.
Holowaty and co-workers found progression of CIN 2 to CIN 3 or worse in 16%
within 2 years, in 25% within 5 years and in 32% within 10 years249.  Östör found
that a total of  27% of all CIN 2 progressed to CIN 3 or worse10.
Lesion grade Regress Persist Progress
to CIN 3
Progress to
invasion
CIN 1 57% 32% 11% 1%
CIN 2 43% 35% 22% 5%
CIN 3 32% <56% - >12%
Table 2.  The course of CIN.  Data from Östör10.
The above mentioned host factors that increase the risk for cervical cancer
must be expected to also enhance the risk for progression of CIN.  The use of
biomarkers to predict CIN progression could have an important potential256.  CIN 1
lesions with diffuse immunohistochemical staining for p16INK4a have been
reported to be more likely to progress to CIN 3 than those that were p16INK4a
negative257,258.  Quantitation of increased Ki67 immunostaining  has strong
prognostic value for progression in early CIN lesions, and are better at predicting
CIN 3 in follow-up than are routine and review CIN grades259-261.  Combined
quantitation of Ki67, Rb, CK13, and CK14 gave accurate information about the
progression risk of early CIN lesions262.  Furthermore, Baak and co-workers
reported that HSILs with combined negativity or low positivity for p53 and pRb
protein in small histologic biopsies were highly likely to persist, contrasting those
in which one of these cell cycle regulators was strongly positive263.  Finally, the
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size of the viral load may be relevant for prediction of progression, as a large load
of high-risk HPV has been reported to represent an increased risk for progression
to CIN 3264-266.
Screening, diagnosis and treatment
As cervical cancer develops through a recognizable and treatable pre-invasive
stage, it should be amenable to screening in agreement with the Wilson Criteria267.
The conventional approach to cervical cancer screening has been the identification
of cells from the cancer or its potential precursors.
The conventional cytological smear
Use of a cytological smear for the diagnosis of cervical pre-invasive and invasive
lesions was demonstrated by Babès and extensively documented by
Papanicolaou268-271.  Cytological screening of asymptomatic women was initiated
on an experimental basis from the late 1940’s, and in Norway in Østfold county in
1959272-276.  Apart from some population-based test projects, up to 1995 the
cytological screening in Norway was based on the initiative of the individual
woman or medical practitioner, a practice termed opportunistic screening.  A
nationwide organized screening program with women being invited for smear tests
every third year, was finally introduced in 1995277,278.  Norwegian and international
guidelines for the follow-up of abnormal cervical smears have been presented279-
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.  Sampling is carried out with a wooden spatula in combination with a brush to
ensure sampling of the ecto- and endocervix.  The sampled cells are smeared onto
a glass slide and immediately fixed by spraying with an alcohol-based fixative.
The average cervical cytological smear contains between 50,000 and 300,000 cells,
and a varying proportion of these may be inflammatory cells and/or erythrocytes6.
Staining is usually done by the Papanicolaou method.
Limitations and alternative methods
The standard cervical cytological smear test has some known limitations267.  The
sensitivity is low, somewhere in the range of 30-87% , resulting from cell
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clumping, admixed blood, frequent inadequate fixation and the fact that only a
limited proportion of the collected cells, as little as 5%, are transferred to the
slide6,248,255,282-290.  Discordance between cytological and histological reports may
result291.  Because the specificity of the test varies from 86 to 100% for the same
reasons, some overtreatment must be expected286,287,290,292,293.  Furthermore,
interobserver variability is substantial248.
Laboratory programs for quality assurance and certification of
cytotechnicians as well as pathologists, may reduce the false-negative rate294,295.  In
our laboratory, cytotechnicians must pass a national exam or the International
Academy of Cytology exam.
In order to increase the sensitivity and specificity of cervical screening,
alternative procedures have been advocated267.  Liquid-based cytology is a new
method of preparing cervical samples for cytological examination.  The collected
cervical cells are suspended in a liquid medium, from where a representative
aliquot is deposited as a thin layer of cells on a glass slide.  Debris, blood and
suboptimal fixation of the cells are avoided, thus reducing the proportion of
specimens classified as technically unsatisfactory267,296,297.  A large meta-analysis
of studies comparing conventional cervical smears with liquid-based cytology
concluded that use of the latter reduces the number of false-negative test results
and the number of unsatisfactory specimens and also that it may decrease the time
needed for examination of specimens298,299.  However, the efficiency of liquid-
based cytology is still debated, and a recent review reported no evidence that it
reduces the proportion of unsatisfactory slides, or detects more high-grade lesions
than conventional cytology300.
As cytological screening for cervical cancer is limited by moderate
sensitivity and low reproducibility, the merit of such programs relies on many
rounds of screening throughout adulthood301.  Testing for high-risk HPV has a
better sensitivity and reproducibility, and would theoretically serve as a better
primary screening test301-307.  Such screening should begin at about age 30, 10-15
years after the average age of sexual debut, avoiding the ages of frequent transient
HPV infections301.  To increase the specificity of HPV screening, women with
positive tests could be examined by cervical cytological smears, and if
cytologically negative, they should be tested for HPV a year or two later to identify
persistent infection301,308.  However, infection with multiple HPV types is
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common58, and type specific persistent high-risk HPV infection as monitored by
genotyping has been shown to identify women at increased risk of cervical
neoplasia more accurately than a single or repeated presence/absence HPV test309.
Primary screening by HPV testing has also been suggested as more cost-
efficient and easier to implement in developing countries297.  HPV DNA testing by
self-obtained samples has been demonstrated as a feasible approach for cervical
cancer screening with sensitivity at about the same level as traditional cytology,
and a good alternative for women who refuse to participate in conventional
screening297,310.
While HPV testing is still not widely used in primary screening, it has gained
an established role as an alternative or supplement to a repeat smear in the triage of
women with ASCUS or LSIL280,281.  Such adjunctive HPV-testing is scientifically
backed up by several studies266,311-313.  However, even if this practice results in a
reduction in the rate of repeat smears, it raises the rates of referral to colposcopy314.
Nevertheless, it has recently been reported to be cost-effective313.
HPV can be detected by PCR, often using a general primer-pair315.  Several
commercial systems for HPV testing are also in use.  The Hybrid Capture II®
Assay (Digene, Gaithersburg, MD, USA) and AMPLICOR® Microwell Plate
Detection (Roche Diagnostics, Indianapolis, IN, USA) are based on detection of
HPV DNA, while the Pre Tect® HPV-Proofer (NorChip AS, Klokkarstua, Norway)
is based on HPV mRNA identification316.  The Hybrid Capture II® Assay has won
wide acceptance304,317.  Theoretically, detection of E6/E7 mRNA could be a more
reliable predictor of cancer risk than the more traditional HPV DNA detection
technologies, and several studies have evaluated these systems318-320.  The Pre
Tect® HPV-Proofer has been found more appropriate for cancer risk-evaluation
than Hybrid Capture II, however, population based studies are needed for solid
evaluation of the predictive values318.
A variety of different screening systems are still under evaluation.  Since
conventional cervical screening is labor-intensive and entirely dependent on human
diagnostic skills, automated, computerized screening devices have been developed,
but they have still not been shown to reduce screening cost, nor to substitute for
manual microscopy by a cytotechnician267,321-325.  Furthermore, screening
approaches utilizing spectroscopic quantification of various physical characteristics
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or measurements of responses to voltage or light are being tested both on cell
samples or directly on the cervix267.
The impact of screening
Well-organized screening programs have been highly effective in reducing the
incidence of cervical squamous cell carcinoma4,278,326.  In the Nordic countries
organized screening programs have had a major impact on the reduction in
incidence and mortality of cervical cancer4,327.  The mass screening program in
Østfold county in Norway resulted in a reduction in the incidence and mortality of
cervical cancer of 22% and 24%, respectively276.  Besides, mass cytological
screening has shifted the presentation of cervical neoplasia from the clinical to the
preclinical stage, with increased detection of pre-invasive lesions241,328,329.
Whereas in the pre-screening era invasive carcinoma accounted for around 80% of
the diagnosed cervical neoplastic lesions, it was reduced to 16-35% after screening
328,330
.  An increased cure rate in the screened population and prolonged survival
times in those with invasive lesions followed330-332.  The incidence of cervical
squamous cell carcinoma and its mortality in Norway have decreased since the
1970’s in parallel with a substantial increase in the use of cervical smears over the
period (Figure 5)333,334 (see also Table 3).  Nevertheless, such opportunistic
screening tended to result in over-examination of young women and insufficient
examination of women over 50 years of age335,336, a fact that could explain the
higher cervical cancer incidence in Norway compared to countries with centrally
organized screening327,337.  Recently, an  increase in cervical cancer incidence in
younger women in Europe has been reported, and has been explained by changing
risk from sexual conduct4.
As cytological screening is labor- and resource-intensive, and it reportedly
results in treatment of many women not destined to develop invasive cancer, the
value of screening has been questioned293,338.
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Figure 5.  Age-adjusted incidence rates of cervical cancer from 1953 to 2004.  From
the Cancer Registry of Norway5.
Year 1962 1972 1982 1992 2002
Smears 115 20600 35900 42000 47000
Table 3.  The development in the yearly number of cervical
cytological smears analyzed in our laboratory.
Diagnosis and treatment
Colposcopy supplemented with histology is advised following a smear report
indicating HSIL or ASC-H and also after persisting LSIL or ASCUS in
combination with a positive test for high-risk HPV29.  The usual approach is to take
colposcopically directed punch biopsies, combined with an endocervical curettage
when the transformation zone is not visualized6,13.  However, significant observer
variability in colposcopic skill and biopsy placement have been reported, in
consequence the biopsy may not in every case represent the true severity of the
lesion248.  Therefore, in cases where cytology suggests a high-grade lesion and the
biopsy is less than high-grade, conization may be required to solve the
discrepancy6.
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Cervical intraepithelial neoplasia is treated by a cone-shaped excision of the
cervix encompassing the transformation zone.  Conizations are usually carried out
using a laser beam, and may vary in size and extent depending on the anatomy and
the woman’s desire for fertility6.  Loop electrosurgical excision procedures may
alternatively be used.  The transformation zone should be excised with adequate
margins of normal endo- and ectocervix to allow pathological examination of the
entire area of the cervix at risk6. Treatment of CIN by administration of
chemopreventive agents such as oral aliretinoin, 4-hydroxyphenylretinamide or
beta-carotene, or locally applied all-trans-retinoic acid has not been succesful250-253.
Cervical cancer is usually treated by radical hysterectomy with pelvic lymph node
dissection, sometimes with adjuvant radiotherapy and/or chemotherapy according
to the stage of disease, as advised by the International Federation of Gynecology
and Obstetrics (FIGO)339.
Archival pathology
With the development of modern cell and molecular biology, clues to individual
physical dispositions and disease can increasingly be detected from nucleic acid
molecules in cell and tissue specimens340.  Huge quantities of specimens are
already stored in various types of biobanks, and large, population-based biobanks
are in progress341-344.
Biobanks
Biobanks are systematized collections of human biological material341,345.  Tissues,
cells or other constituents of the human organism from large numbers of persons
are stored for a variety of purposes341.  The biobanks may be classified
accordingly.  Diagnostic biobanks consist of material used diagnostically, for
example the tissue – and cell archives of pathology laboratories.  Therapeutic
biobanks are collections of biologic material intended for use in medical treatment,
for instance frozen, fertilized ova and donor blood banks.  Human biological
material used for scientific or developmental studies are kept in research biobanks.
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Commercial biobanks now also flourish, for the most part being utilized by the
pharmaceutical industry and medical diagnostic companies346.
The pathology archives
The new preparation techniques, including fixation, paraffin embedding and
microtome sectioning, together with improved light microscopy were important
prerequisites for the cellular pathology that revolutionized medicine in the second
part of the 19th century347.  As formalin-fixed and paraffin-embedded tissue was
found to be lasting, diagnostic specimens have routinely been kept in Norwegian
pathology archives from around 1930.  Specimens from people born in the middle
of the 19th century are thus kept in the archives, and assuming short generation
gaps, tissue material from up to 5 or 6 generations of a family may thus exist.
On a national basis, the number of specimens in Norwegian pathology
archives are formidable.  In the year 2000, 340,000 biopsies and 560,000
cytological specimens were examined348.  Every specimen may consist of several
tissue blocks, in some cases more than 50.  In the same year, 5000 autopsies were
carried out348.  A recent calculation showed that a total of 20 million paraffin
embedded tissue specimens were kept in the 26 Norwegian pathology
laboratories341.  These represent nearly 5.5 million patients over a time span of
more than 70 years.  When cytological specimens are included, the total number
reaches 10 million patients.  All age groups are represented, and most women 18
years or older are included.  In addition, corresponding files containing the clinical
and pathological diagnoses are usually available.
New methods and applications
During the last decade we have seen the application of various molecular
biological techniques to the examination of archival specimens. DNA can be
retrieved from formalin-fixed, paraffin-embedded tissue blocks, as well as from
stained sections and cellular smears.  Identification of genes and genetic alterations
such as mutation in cancer cells, can be carried out on the basis of the retrieved
DNA349.  Amplification of the DNA segment in focus using polymerase chain
reaction (PCR) is the usual approach, yielding substrate for further analyses.
32
Archival specimens can be examined by standard molecular biologic techniques
for genotyping and mutation analyses, such as DNA sequencing, restriction
fragment length polymorphism (RFLP) determination, allele-specific
amplification, and detection of mRNA using the reverse transcription-polymerase
chain reaction (RT-PCR).  Quantitation of gene expression or gene copy number
can be done using real-time PCR350,351.  Furthermore, human telomere lengths at
the individual cell level may be assessed in sections from formalin-fixed paraffin-
embedded tissues352.  In situ hybridization and in situ PCR techniques allow the
demonstration of specific nucleic acid sequences in their cellular
environment353,354.  The specificity of the molecular analyses can also be enhanced
using laser-assisted microdissection of cell groups or single cells355,356.
On the protein level, the continuous development of new antibodies in
combination with modern antigen retrieval techniques  have produced a broad
selection of antibodies well suited for qualitative immunohistochemical detection
of microorganisms and gene products in formalin-fixed, paraffin-embedded
tissue357-360.  Tissue array systems allow for parallel analysis of hundreds of
specimens361.
Using electronic image analysis systems, microanatomic measurements may
be carried out on paraffin sections362.  By deparaffination and proteinase treatment,
cells from archival tissue are rendered suitable for suspension and staining with
fluorescing dye permitting flow cytometric analyses363.  Ploidity in malignant
tumors may be assessed cytometrically or through image analysis364-366.  Ultra-
structural studies using electron microscopy are well established367, while high-
resolution three-dimensional, computerized pictures may be examined using
confocal laser scanning microscopy368,369.
Genes, proteins, microbiological agents and other substances can now be
examined and correlated to morphological changes in cells and tissues from a vast
array of diseases.  Characterization of microbiological agents is now feasible, as
exemplified by Helicobacter pylori, polio virus and Spanish influenza virus370-372.
Little material has been wasted from Norwegian pathology archives.  Thus,
biomedical examinations of archival specimens from a large part of a stable
population with population data at hand, may constitute a potent research tool.
However, sensitive data may be revealed, for instance information on venereal
disease, deviating parentage or information about inherent disease.  Also, revised
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pathological diagnoses after renewed examination or special analyses, may be
inconvenient to the pathologist.  Thus, the use of biobanks for research raises
relevant questions about medical, legal and ethical implications for confidentiality,
autonomy and community benefits373-375.  Regulatory provisions attending these
issues are now generally being implemented341,376,377.  As future scientific
developments must be expected to increase the value of the archival material, the
biobanks should be well kept and not emptied.
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AIMS OF THE STUDY
As our understanding of the pathogenetic mechanisms of cervical cancer is rapidly
developing and new technology is available, established diagnostic principles and
practices need confirmation.  The main approaches in this thesis were to examine
the characteristics of the traditional principles and practices of cytological
diagnostics of cervical neoplasia in Western Norway during the last 20 years, to
establish whether the viral factor in cervical neoplasia changed during a time span
of three quarters of a century, and to examine the PI3K-AKT pathway in cervical
neoplasia.
On this basis the following objectives were formulated:
1. To characterize the compiled pathology database smear histories in women
with cervical intraepithelial neoplasia or squamous carcinoma and to assess
its relevance to the present diagnosis.
2. To determine the effect of resection margin status, HPV status and p53
expression on lesion-free survival after laser conization for CIN 3.
3. To compare the level of papillomavirus changes in cervical lesions that
progressed to CIN 3 to that in lesions that did not progress.
4. To explore the practicability of sequencing DNA from up to 75 years old
formalin-fixed, paraffin-embedded tissue and to examine HPV subtype
distribution in cervical neoplasia between 1931 and 2004.
5. To determine the status of the PI3K-AKT pathway in cervical neoplastic
tissue in order to elucidate some of the biological mechanisms in cervical
carcinogenesis.
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SUMMARY OF THE PAPERS
Paper I
The previous smear history (1981-88) and short term outcome (up to and including
1992) in all 850 women with a cytological diagnosis of cervical neoplasia in 1989
were assessed.  In every case, the cytological and histological diagnoses recorded
were read out from the hospital’s Norsk Data database and entered manually into a
relational database program.  The data comprised 6314 cytological specimens and
1824 histological specimens.  One half of the women had a previous history of
only negative smears, irrespective of the type of lesion present in 1989.  About
every third woman had a previous diagnosis of CIN, while about every fifth
woman lacked previous smears.  In 1989, those without previous examination
more often than the previously screened women had a diagnosis of invasive
cervical squamous cell carcinoma.  Moreover, we found that the women’s previous
smear histories were similar, independent of the current grade of CIN in 1989.
Paper II   
Lesion-free survival was assessed in 598 women who had undergone laser
conization for cervical intraepithelial neoplasia grade 3.  The state of the resection
margins was recorded and related to the findings on follow-up, up to 15 years post-
operatively.  Lesion-free survival times were analyzed by the Kaplan-Meier
method.  Furthermore, every fifth case was examined for human papillomavirus
infection using DNA in-situ hybridization with probe cocktails against HPV types
6/11, 16/ 18 and 31/ 33/ 35, respectively .  Also, every fifth case was examined for
p53 expression using immunohistochemistry with the monoclonal antibody DO-7
which recognizes epitopes of both the wild-type and mutant human p53.  Lesion-
free survival was significantly more common after complete than incomplete
excision of cervical intraepithelial neoplasia.  In the latter, lesions tended to appear
shortly after surgery, indicating the presence of residual disease.  The few lesions
appearing later during follow-up were evenly divided between those with and those
without complete excision.  No association could be demonstrated between lesion-
free survival and HPV DNA status or p53 immunoreactivity.  We concluded that
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the presence of CIN in the cone margin gave strong indication of potential
treatment failure.  In its absence, laser conization was a highly effective treatment
of CIN 3.
Paper III
The presence of HPV was examined in archival material from two groups of
women with progressive and non-progressive CIN, respectively.  Using
morphological criteria for HPV on cervical smears and in situ hybridization on
formalin-fixed paraffin-embedded tissue no significant difference was found
between the two groups.  PCR with a general HPV primer pair was carried out on
the cases that were negative on in situ hybridization.  Combined evaluation of the
in situ hybridization and PCR results showed that HPV was found significantly
more often in the cases with lesions progressing to histologically proven CIN 3.
Paper IV
In this paper we studied the practicability of sequencing DNA from formalin-fixed,
paraffin-embedded tissue stored for up to 75 years and investigated  human
papillomavirus subtype distribution in cervical neoplasias from the period 1931 -
2004.  Three protocols for DNA retrieval were examined using sequencing of p53
exons 7 and 8 as test system for cellular DNA quality.  Magnetic bead DNA
extraction proved advantageous as it gave superior specimen purity and effortless
sequencing.  Successful sequencing was achieved in more than 70% of the
specimens from 1931-60.  Mutations in p53 exon 7 and 8 were uncommon.  Next,
magnetic bead DNA retrieval was utilized to study viral subtypes using general
primer pair PCR with sequencing of the products in a series of 97 cases of
neoplastic and non-neoplastic cervical specimens from 1931-1960 and 73 similar
cases from 1992-2004.  HPV was detected in 61% of neoplastic specimens from
1931-60, and in 89% of those from 1992-2004.  In specimens from 1931-34 only
HPV type 16 was detected, whereas in the specimens from 1940 and later other
HPV subtypes were identified in one third of the cases.  The difference was
statistically significant and suggests an increase in papillomavirus subtype
heterogeneity in Western Norway after 1930.  The results demonstrated the utility
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of studying cancer genotypes in up to 75 years old formalin-fixed, paraffin-
embedded specimens.
Paper V
This work was a molecular analysis of the PI3K-AKT pathway in uterine cervical
neoplasia.  We studied 46 specimens of formalin-fixed, paraffin-embedded cervical
neoplastic tissue.  The activation state of the PI3K-AKT pathway was assessed
immunohistochemically using an antibody with specificity towards serine-473
phosphorylated AKT.  AKT phosphorylation was found in 39 out of 46 examined
specimens.  In order to examine the possible molecular basis for this activation, we
searched for PIK3CA amplification using quantitative real-time PCR.  PIK3CA
gene copy number was estimated to be 3 or more in 28 out of 40 successfully
examined cases.  In addition, a PTEN mutation analysis of all nine PTEN exons
was carried out, but except for one metastasis with a heterozygous mutation in
exon 9 (V369I), all cases showed normal PTEN sequence.   Immunohistochemical
staining for PTEN was strong in all lesions.   We concluded that an increased
activation state of AKT kinase appeared to be present in cervical carcinogenesis,
and could be accounted for by PIK3CA amplification, whereas PTEN mutation
seemed to be of little importance.
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DISCUSSION
Study material
This work is based on the routine material from Department of Pathology, the
Gade Institute, Haukeland University Hospital.  The specimens came from general
practitioners, gynecologists and hospital gynecological departments.  The
cytological specimens in paper I, II and III, resulted from the standard
opportunistic screening of asymptomatic women (including the follow-up
specimens generated), the examinations of symptomatic women and the follow-up
of women that had been treated for CIN 3.  The histological specimens either
resulted from follow-up of cytological findings or the clinical work-up in
symptomatic patients.  The study material must be expected to be representative of
the cervical, diagnostic specimens from this region.
The records of  this department have been computerized since 1981.
Information on specimens diagnosed before that year was not included in the
study.  In the Norsk Data system (Norsk Data, Oslo, Norway) used in this
department up to 1997, data on specimens and diagnoses were manually entered
from the typed specimen reports, while the DocuLive Patologisystem (Siemens
Norge, Oslo, Norway) used later included full computerization of reports and
records.  In the Norsk Data system the cytological diagnoses were recorded using
the SNOP (Systematized Nomenclature of Pathology, the College of American
Pathologists) code up to 1992, later the  SNOMED (Systematized Nomenclature of
Medicine, by SNOMED®International, the College of American Pathologists)
codes were used.  The diagnoses used in paper I-III were retrieved from printouts
of the computerized archives where typing or coding errors may have occurred.
However, in every case where a recording error was suspected, the original report
was checked.
As the specimens have been collected by many different medical
practitioners over an extensive time period, the indications for the cyto- and
histological examinations may not have been totally consistent throughout the
study, and the representativity of the cells or tissues retrieved may have varied.
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Likewise, inconstant quality of the pre-laboratory preparational techniques,
including fixation, must be expected.  Further, as the specimens were processed in
a large, routine pathology laboratory, suboptimal laboratory processing (i.e.
fixation, embedding, microtome cutting, or staining) of some specimens cannot be
excluded, and may have influenced the representativity of the material.
All diagnoses were translated from the dysplasia terminology to the CIN
terminology, otherwise all diagnoses of pre-invasive lesions in paper I and III were
the original ones set by the pathologists at this laboratory.  The value of light-
microscopy in diagnostic cytology and histology rests on the observer’s
interpretation of complex images.  Interobserver variation in the analyses of
cervical cytological and histological specimens is a common phenomenon248,378-382.
Thus, a review of all 6314 cytological smears and 1824 histological specimens
could have increased the diagnostic consistency of the study material.  However, as
one of the aims of this study was to characterize the compiled pathology database
smear histories in women with CIN, such an approach was not considered to be
practical.  Also, it may be noted that a similar approach has later been used in the
large Canadian cohort study of progression and regression of cervical dysplasia
during 1962-1980249.
Besides, discordance between the cytological and histological evaluation of
CIN has been reported291.  Use of MIB-1 and/or p16 immunohistochemistry can
reduce false-negative and false-positive biopsy interpretation and thereby
significantly improve cervical pre-cancer diagnosis256,259,382,383.  Such
immunostaining was, however, not in routine use in the diagnostic laboratory in
this department during the study period of paper I-III.
In papers I-III, specimens diagnosed as inflammatory or undetermined (i.e.
M4000/40000 or M6900/M69000) were recorded as negative for neoplasia.
However, it was at that time in such cases standard procedure to advice the
clinician to take a repeat specimen.  The diagnosis of HPV changes was not in
general use during the time period covered by papers I-III.  Some cases with HPV
may have been interpreted as negative, while others may have been labelled CIN 1,
as reported24.
About 18% of cervical cytological specimens from the region covered were
analyzed outside this laboratory in 1989 (personal communication from former
head of cytopathology, dr. Elsa Skaarland).  In some cases of interest, cervical
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specimens may have been sent to other pathology laboratories.  Accordingly, there
is a possibility that relevant cytological or histological diagnoses in some case may
not have been known to us.
Methodological aspects
Immunohistochemistry
Immunohistochemistry is the use of labeled antibodies for detection of antigens in
tissue sections.  The commonly used indirect method involves an unlabeled
primary antibody reacting with tissue antigen and a labeled secondary antibody
reacting with several sites on the primary antibody, resulting in signal
amplification and increased sensitivity.  The peroxidase anti-peroxidase method or
the avidin-biotin complex method are commonly used for labeling of the secondary
antibody384,385.  Antigen retrieval by  pre-treatment of the tissue with proteolytic
enzymes or heating is commonly used to increase the sensitivity of the assay.
Suboptimal antibody concentration, antibody denaturation or low antigen density,
as well as post-fixation loss of antigen, are common causes of negative results386.
Low specificity may in some cases result from antibody cross-reactivity, non-
specific binding, tissues with endogenous peroxidases or avidity for the avidin-
biotin complex, or, notably, entrapment of normal tissues or tissue proteins by
tumor cells386.  Positive controls to test the protocol and negative controls to test
for the specificity of the antibody were applied in this study.
A major cause of variation in the reproducibility of immunohistochemical
staining is induced by tissue fixation and, to a lesser degree, tissue processing387.
As we worked with routine, diagnostic biopsies and surgical specimens covering a
long time span, some variation in tissue fixation and tissue processing must be
expected.  Also, unbuffered formalin was used before 1970.  The application of
laboratory robots, for instance the DakoTechMate™ (Dako, Denmark) that was
used in paper V,  should increase standardization and reproducibility of the
immunohistochemical staining.  Quantitative, objective methods may be used to
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reduce interpretational errors and improve the reproducibility of
immunohistochemical assessments256.
Immunohistochemistry with the monoclonal mouse antibody DO-7 (Dako)
with application of microwave antigen retrieval and the avidin-biotin-peroxidase
complex was manually carried out in paper II for examination of p53 expression.
DO-7 is a widely used antibody that binds epitopes of wild-type and mutant p53388-
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.  In paper V, immunohistochemistry was applied for assessment of the
phosphorylation status of AKT using the polyclonal goat anti-phospho-Akt
antibody #9277 (Cell Signaling Technology, USA), applying the
DakoChemMate™ avidin-biotin kit with peroxidase/DAB (Dako).
Phosphorylation state-specific antibodies have been reported to raise some
interpretive problems as the staining patterns may be complex391, and, accordingly,
there are no standard systems for scoring of P-AKT staining392.  Therefore, we
developed a system based on recent publications392-394.  Also, due to a report of
rapid dephosphorylation of phosphoproteins in human tumor specimens, it has
been emphazised that caution should be applied in the interpretation of
phosphorylation state395.
In situ hybridization
In situ hybridization (ISH) is a technique for visualization/localization of specific
nucleic acids in tissue sections by the use of a labeled nucleic acid probe with base
sequence complementary to the sought DNA or RNA, thus enabling hybridization
between probe and target after a denaturating step396,397.  The tissue sections may
be treated with detergent or proteinases such as proteinase K in order to
permeabilize the membranes. The probe must have sufficient access into the cells
so that it can bind to the target. The degree to which the cells are permeabilized
affects the degree of specificity of ISH.  Cloned RNA or DNA, or synthetic
oligonucleotides are used as probes386.  They can be labeled directly, or indirectly,
with a specific antibody or a labeled binding protein used to detect another
molecule that is attached to the probe sequence.  Labeling can be done with
radioactive substances, but  peroxidase, biotin or digoxigenin is more commonly
used today386,398,399.  Digoxigenin labelled probes have been found more sensitive
than biotinylated probes400.  The probe design and the temperature, pH, and salt
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concentration of the buffer solution will control the degree of specificity of probe
to target hybridization.  “High stringency” conditions will only allow hybridization
of probes with very similar homology to the target sequence, while “low
stringency” conditions will allow a probe to bind with less specificity.  ISH has
been widely used to identify HPV DNA in tissue sections, and signal amplification
systems have been developed401-403.
In situ hybridization was used in paper II and III for studying the presence of
HPV DNA in tissue sections.  In paper II, we applied three commercial cDNA
HPV probe sets reacting with HPV types 6/11, 16/18 and 31, 33, 35, respectively,
and hybridization kit (ViraType and Digene Tissue Hybridization Kit, both
Digene, USA), while in paper III, a commercial pan cDNA HPV probe and
hybridization kit (Omniprobe™ and Digene Tissue Hybridization Kit, both  from
Digene) covering HPV types 6, 11, 16, 18, 31, 33, 35, 42, 43, 44, 45, 51, 52 and
56.  Thus, in paper III, the non-carcinogenic types 6, 11, 42, 43 and 44 were
covered, while some of the types now considered carcinogenic, i.e. 39, 58, 59, 68,
73, 82 and probably carcinogenic, i.e. 26, 53 and 66, were missing43.  The exact
stringency of these commercial systems have not been given by the manufacturer,
but has been reported to be low404,405.  The sensitivity has been found similar to
radioactive in situ hybridization, filter-, dot blot-, and Southern blot
hybridization404,406.  A detection limit of about 20 viral DNA copies per cell has
been reported407.
DNA retrieval from formalin fixed tissue
Effective retrieval of genomic DNA is needed for gene analysis of formalin fixed,
paraffin embedded tissue samples408,409.  Formaldehyde reacts with DNA through
interaction with hydrogen bonds, induces protein crossbindings, and
hydroxymethylation of the nucleic acids.410.  Removal of paraffin wax using
organic solvent, followed by enzymatic protein digestion, with or without
purification by phenol/chloroform extraction has been the conventional
approach411-413.  In this study, genomic DNA was extracted from formalin-fixed
paraffin-embedded tissue samples in paper III, IV and V. Several methods for
DNA retrieval were used.  In paper III, it was done by an easy and fast method
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applying xylene dewaxing, followed by tissue- and macromolecule decomposition
by boiling for 7 minutes414.  This method yielded DNA of a quality sufficient for
successful PCR using the GP5+/6+ primer pair.  In paper IV, we tested three
different procedures for DNA isolation from old formalin-fixed, paraffin-
embedded tissue.  Two of these procedures included conventional xylene
deparaffinization, followed by proteinase K digestion, overnight in one procedure,
while for six days in combination with a chelating agent and detergent in the
other411,412.  Purification by phenol/chloroform extraction was not included, as
inhibition of the Taq polymerase by carry-over phenol has been reported415,416.
Both procedures yielded low purity DNA.  However, in both cases it could be used
for DNA sequencing.  In the third procedure, the GenoPrep™ DNA from Tissue
Kit was run on a GenoM™-48  robotic workstation (both from QIAGEN,
Germany).  This system, which was also used in paper V, is based on heat pre-
treatment for dewaxing, thus avoiding the use of organic solvent, followed by
proteinase K digestion and DNA extraction using magnetic beads in the presence
of chaotropic salts.  The positively charged magnetic beads will attract the
negatively charged DNA.  This procedure rendered high-purity genomic DNA.
The time-effectiveness of the procedure makes up, at least in part, for the
expensive equipment and reagents.  It therefore became the selected method when
the isolated DNA was to be used for sequencing or quantitative real-time PCR
(papers IV and V).
PCR
PCR is a powerful technique used to make a large number of copies of a target
DNA sequence, thereby producing substrate for further analyses417.   The principle
is automated heating and cooling for 30-45 cycles of denaturation of the nucleic
acids (at about 94°C), annealing between templates and primers (at about 50-
55°C), and extension (at 72°C ) by the activity of a heat-stable DNA polymerase,
providing an exponential increase of the number of copies of the target DNA
sequence.  Primer annealing is the rate limiting process in PCR418.  When working
with template DNA from formalin-fixed, paraffin-embedded tissue, where DNA is
degraded into shorter segments, PCR products should be optimized to a length less
than 200 basepairs, even if successful amplification of longer products have been
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reported410,419.  PCR was used in paper III for studying the presence of HPV DNA
using the general primer pair GP5+/6+.  Detection of a 150 basepair long PCR
product on agarose gel electrophoresis served as identification of HPV.  This
primer set has been reported to amplify HPV 6, 11, 13, 16, 18, 30, 31, 32, 33, 35,
39, 40, 43, 45, 51, 52, 54, 55,56, 58, 59, 66, thus missing the carcinogenic types
68, 73 and 82, and the probably carcinogenic types 26, 53 and 6643,315. Use of
multiple PCR primer sets would, of course, have optimized the sensitivity of viral
detection420.  The primer pair GP5+/6+ was also used in paper IV.  However, here
a biotinylated GP5+ primer was applied for easy purification of the PCR product
using streptavidin-coated magnetic beads, followed by sequencing of the PCR
products to identify HPV subtypes.   Even if the GP5+/6+ primer pair is widely
used in HPV research and diagnostics, it may not be optimal, as it recently has
been reported that PCR primers that target the L1 region, like GP5+/6+, may miss
some cases of advanced disease.  The reason is that the LI regions sometimes are
lost during integration of viral DNA into the host genome421.  Also, in paper IV
PCR was used in the sequence analysis of p53 exons 7 and 8 with product sizes of
171 and 230 basepairs, respectively.  In paper V, analysis of  PTEN was done using
11 PCR product to cover the 9 exons, with PCR product lengths between 147 and
265 basepairs.
The great sensitivity of the PCR method renders the process of sample
collection, sample processing and amplification susceptible to contamination by
plasmids, DNA from other samples, and PCR products (carry-over).  Paraffin
blocks were cut using gloves, with clean instruments and fresh microtome-blades.
The preparation of the PCR reaction mix, the addition of specimen to the mix, the
amplification, and the analysis of the PCR products were carried out in separate
rooms using dedicated pipettes with filter plugged tips.  Negative controls were run
with each amplification, and were at no time positive during this study.
Sequencing of DNA
The dideoxy method is the commonly used method for determination of the
nucleotide sequence of a DNA fragment422.  This method was used in paper IV for
the p53 analysis and HPV subtype identification, and in paper V for the PTEN
mutation analysis.  Even if DNA sequencing is a standard method for mutation
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analysis, it may be hampered by some problems.  False positive results may occur
as a result of PCR-induced changes in the base sequence.  Error rates of
thermostable DNA polymerases have been reported between 2.1 x 10-4 to 1.6 x 10-6
misincorporations per nucleotide per extension423,424.  However, to overcome the
possibility of PCR-induced sequence alterations, all mutations detected in this
study were verified by repeated PCR amplification and sequencing from tumor
DNA.  False negative findings may result if DNA is extracted from specimens
where the neoplastic cells make up only a minor fraction of the cells, with non-
neoplastic, i.e. stromal and inflammatory, cells dominating.  To overcome this
problem, in paper V, tumor tissue was dissected manually from the specimens
under microscopic guidance.  Use of laser-assisted microdissection of tumor tissue
could probably further have increased the cellular specificity of this assay355,356.
Quantitative real-time PCR
Quantitation of gene dose or gene expression can be done using real-time analysis
of the polymerase chain reaction425.  The principle is that a fluorescing signal is
released from the products of every PCR cycle, with the signal intensity being
proportional to the quantity of accumulated PCR product426,427.  The cycle number
at which the reporter dye emission intensity rises significantly above background
noise is called the threshold cycle (CT) (Figure 6).  The higher the template
concentration, the lower the measured CT. The CT is determined at the exponential
phase of the reaction, where none of the reaction components are limiting355.  Real-
time measurement is therefore more robust and dependable than conventional
quantitative PCR methods using end-point measurements, where only a slight
variation in limiting reaction component concentrations may markedly affect the
quantity of PCR end product, thus resulting in poor precision.  The method has
successfully been applied to studies of nucleic acids from formalin-fixed, paraffin-
embedded material356.  Quantitation of gene copy number is often done using a
standard curve428.  However, if amplification of target and reference are equally
efficient, the comparative CT method, which does not depend on astandard curve,
can be used429.
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Figure 6.  Real-time PCR.  CT is the threshold cycle number at which the
reporter dye emission intensity rises significantly above the baseline
background noise. The higher the template concentration, the lower the CT
measured. The relative fluorescence, ∆Rn, will be proportional to the
quantity of PCR-product.
Quantitative real-time PCR was used in paper V for assessment of relative
PIK3CA gene copy number using the glucokinase gene (GCK) as reference.  As we
did not succeed in designing primer pairs for target and reference gene that worked
together in a multiplex reaction, three separate parallels were run for both target
and reference gene in every CT determination assay, with the mean CT value used
in the calculations of gene copy number.  A multiplex assay with both PCR
reactions run in the same tube would probably have been beneficial, as it would
have excluded well-to-well variability, reduced reagent costs, time consumption,
saved sample DNA and increased throughput.  In particular, when examining slight
changes in gene copy number, it is crucial to avoid well-to-well variation in
reagent volumes.
Diagnostics and treatment
Diagnostic and therapeutic aspects are dealt with in papers I and II.  The focus is
on the merits of the screening system and treatment used at the time period
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examined.  Paper I characterizes the compiled smear histories between 1981 and
1992 of all 850 women that were given a cytological diagnosis of CIN by this
laboratory in the index year, 1989.  In that year, 54% of the cases were given a
diagnosis that would equal to HSIL in the Bethesda classification.
Moreover, the finding that 49% of those HSIL cases had a smear history of only
negative specimens during 1981-88, may reflect the common existence of fast-
developing pre-malignant lesions430.  However, it can alternatively be seen as a
demonstration of low sensitivity of the cervical cytological smear test, and as such
underscoring the need for a more sensitive screening test, possibly a test for high-
risk HPV.  On the other hand, the finding that nearly 60% of those diagnosed with
invasive carcinoma in the index year lacked earlier cervical smears during 1981-
88, brings attention to the flaws of the opportunistic screening system used at the
time.
Paper II examines the merits of laser conization in 598 women treated for
CIN 3, with up to 15 years follow-up. As the follow-up diagnoses used in paper II
were those originally given, interobserver variation must be expected.  More
consistent and solid follow-up status could have resulted from a re-examination of
all follow-up diagnoses248.  Soutter and co-workers recently performed a meta-
analysis of the risk of invasive cervical cancer after treatment of CIN, including
data from paper II431.  In paper II, the risk of residual disease after conization was
found to be significantly higher in cases where CIN was present in the resection
margins, in line with other reports432.  It is of note that the presence of CIN in the
endocervical resection margin later has been reported to be a predictor of HPV
persistence after conization433.  Further, in paper II, the risk of post-conization CIN
was found to fall with time, in keeping with the conclusions of Soutter et al.431.
However, as post-conization CIN sometimes occurred late, there is reason to
recommend annual cytological smears for 10 years after conization, in agreement
with Soutter et al.431.  Also, in paper II, HPV status and expression of p53 in the
conization specimens were correlated to occurrence of residual or recurrent
disease.  Cervical carcinomas with mutations in p53 and no or low papillomavirus
load had at that time recently been reported434.  However, in view of the later
knowledge of a virtual non-existence of HPV-negative cervical neoplasia and p53
generally being abrogated by the E6 oncoprotein43,46, the possibility that p53
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expression or HPV status in the cone specimen could be potential prognostic
factors after treatment for CIN seems to be of little concern.
Mechanisms of cervical neoplasia
The biological mechanisms of cervical neoplasia are the focus of papers III-V.  In
paper III the presence of HPV infection was examined by morphology, in situ
hybridization and general primer PCR in CIN that progressed to grade 3 and in
CIN that did not reach grade 3.  As the cases studied here were not randomly
picked, but selected according to a set of given criteria, the representativity of the
two groups may be questioned.  Reservations as to inconsistency and
reproducibility of CIN grades apply, as the diagnoses used in this paper were those
orginally given in the diagnostic routine.  Also, it must be remembered that the
histological diagnosis of CIN3 results from the fact that a histological specimen
was made on the basis of a clinical decision and the smear history, and may
therefore not necessarily be a valid reflection of the natural course of CIN.
Besides, in the non-progressive cases, tissue for HPV examination by in situ
hybridization and PCR was available in only 38 cases out of 133.  There is thus
reason to question the representativity of these 38 cases.  Further, the examination
of material scraped off from cervical smears using general primer PCR in cases
lacking tissue, could have been a relevant option.  Subtyping of HPV would also
have been of interest here.  It could have been done using the ViraType (Digene)
probe set instead of the Omniprobe™ (Digene).  However, as DNA sequencing
was not established in this laboratory at that time, HPV subtyping by GP5+/6+
PCR product sequencing was not easy to implement.  Many cases that had
progressed to CIN 3 were HPV DNA negative by in situ hybridization, but positive
on general primer PCR.  In view of the greater sensitivity of PCR, this could be
seen as a demonstration of low viral load in some cases of CIN 3.  HPV was
detected on PCR in 69% of the CIN 3 cases tested, in line with an earlier study
using type specific PCR435.
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In paper IV, archival cervical cancer specimens dating back to 1931 were
examined for presence of HPV.  Different methods for retrieval of genomic DNA
from formalin-fixed, paraffin-embedded tissue were tested, and a commercial
system utilizing magnetic beads was found more efficient than the conventional
techniques.  As the tissue archives of this department are vast, the establishment of
an effective method for examination of old DNA opens for further studies of
genetic variation in disease.  The HPV findings demonstrate that, even if the
distribution of genital HPV infections is closely related to the human factor, and
cervical cancer incidence has been changing over time, HPV infection as a
causative factor in cervical cancer has been persistent for at least 75 years.
Furthermore, the indication of increasing viral subtype heterogeneity during the
period studied is of interest, as geographic variation in HPV subtype distribution is
well known43.  As the increasing heterogeneity was detected in cancer specimens
from 1940 and onwards, the change in HPV subtype prevalence must have
occurred at a minimum of about 15  years earlier, i.e. in the mid 1920’s.
The findings reported in paper V of an activated AKT kinase, probably
caused by low-level amplification of the potential oncogene PIK3CA, add to the
known inactivation of tumor suppressors p53 and pRb caused by HPV
oncoproteins in cervical carcinogenesis.  In general, amplification represents a
major molecular pathway by which gene expression can be constitutively enhanced
above the level of physiologically normal variation436.  Therefore, amplification
can confer a selective advantage to cells under stress, and is considered important
in carcinogenesis, as well as in development of chemoresistance437,438.
Amplification may be a manifestation of genetic instability, which is present in
most cancers438,439. Genetic instability, as earlier discussed, is induced early in
cervical carcinogenesis by the expression of viral oncoproteins E6 and E796,102.  It
must be noted that most cancers show a multiplicity of genetic changes or
mutations, the great majority of which probably have no significant effect on tumor
growth or progression440.  Functional analyses are needed to distinguish
noncausative “passenger” mutations from those with true roles in
carcinogenesis441.  In colon cancer, experimental studies have demonstrated that
the most frequently observed PIK3CA mutations are functionally overactive, and
thus likely to be involved in carcinogenesis117,126,442.  Amplification must be
expected to yield too much of the normal gene product, which is reflected in this
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study by the detection of an increased phosphorylation status of AKT.  However, it
would be of interest to assess the PI3K expression in cervical cancers.  As the
PI3K-AKT pathway serves a fundamental role in connecting growth signals from
outside the cell with various parts of the cell’s machinery for proliferation and anti-
apoptosis, the activation of this pathway in cervical cancer must be expected to
have a major impact on tumor growth and progression.  It may well prove to be a
necessary second hit in cervical carcinogenesis after integration of HPV DNA45,181.
Perspectives on prevention and therapy
Effective immunization of women against HPV must be expected to reduce the
incidence of cervical cancer443-445.  However, as HPV subtype distribution varies
with geographic localization43,44 and possibly with time, as indicated in paper IV,
continuous global monitoring of HPV subtype prevalence may be required in order
to maintain potent vaccines.
As demonstrated by the successful use of kinase inhibitors in cases of
chronic myelogenous leukemia with BCR-ABL kinase, gastroeintestinal stromal
tumors displaying mutations in the c-KIT gene, breast cancers with HER2 gene
amplification and non-small cell lung cancers with mutated EGFR receptor
tyrosine kinase, mutated kinases are ideal drug targets446.  Targeting PI3K-AKT
has been considered a rational therapeutic approach in cancers with deregulation of
this pathway118,144,447,448.  Hypothetically, restriction of tumor cell survival,
proliferation, angiogenesis, invasion and metastasis would be anticipated.  Besides,
as the p53 apoptotic response requires downregulation of the PI3K-AKT pathway
through the transcriptional activation of PTEN, it has been speculated that
simultaneous inhibition of PI3K-AKT and activation of apoptosis downstream of
p53 might have synergistic effects that could be utilized therapeutically in tumors
that carry p53 mutations114.
The presence of cancer-specific mutations and amplifications in PIK3CA that
activate PI3K-AKT signaling make the p110α catalytic subunit of PI3K a
promising drug target118. Several PI3K inhibitors exist, most notably wortmannin,
demethoxyviridin and LY294002449,450.  Even if wortmannin and LY294002 have
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been shown to induce growth inhibition in several model cancers, they have been
regarded as unsuited for clinical use due to toxicity and low specificities and
potencies144,449-454.  PI3K inhibitors used as a supplement to radiotherapy or
cytotoxic agents may be a future treatment option in cervical cancer.  This is
emphasized by a recent study where increased expression of phosphorylated AKT
in cervical cancer specimens was demonstrated to be associated with radiation
resistance of the tumor455.  Further, inhibition of PI3K by LY294002  has been
shown to radiosensitize cervical cancer cell lines456.  Interestingly, LY294002 has
been demonstrated to block export of doxorubicin from drug-resistant colon cancer
cells, resulting in massive cancer cell apoptosis457.  The field is constantly
developing, and selective and potent PI3K inhibitors must be expected in the
future.  They may show clinical utility alone or in combination with conventional
chemotherapy.
Targeting PDK1, AKT or effectors downstream of AKT is also a promising
therapeutic strategy114,458.  The mTOR inhibitor rapamycin reportedly restrains
metastatic tumor growth and angiogenesis in tissue culture and mouse
models144,459.  The effectiveness of various rapamycin derivatives are currently
being tested in breast, renal, non-small cell lung, cervical and uterine carcinomas,
as well as anaplastic astrocytomas, mesotheliomas and soft tissue sarcomas122,458.
As activated AKT in experimental systems has been demonstrated to
promote drug resistance by restraining apoptosis, targeting PI3K-AKT in AKT
expressing tumors  to restore cancer drug sensitivity may be a fruitful
strategy460,461.  There are already indications that mTOR inhibitors may be
effective in overcoming resistance to cytotoxic agents in a variety of malignancies,
including carcinomas458,461. However, the recently described paradoxical effects of
AKT (see Background) must be taken into account when designing AKT inhibitory
drugs178-180.
Because cervical cancer growth is dependent on continuous expression of E6
and E7, anti-HPV gene therapy could have a therapeutic potential462.  In vitro
studies have indicated that inhibition of E6 and E7 gene expression by antisense
RNA, ribozymes or siRNA, results in loss of the transformed phenotype462.
However, in lack of an effective delivery system for anti-HPV gene therapy,
clinical trials are still awaited.  Nevertheless, substances specifically targeting
53
PI3K-AKT used in combination with anti-HPV gene therapy, may well prove to be
the future adjuvant treatment modality of choice in cervical cancer.
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CONCLUSIONS
Based on this work, the following conclusions may be drawn:
1. In cases with CIN diagnosed in the index year, the pathology database
smear record showed no previous smear in nearly 20%, only negative
smears in about half of the cases, CIN 1 in about 15%, CIN 2 in about 10%,
and a diagnosis of CIN 3 or carcinoma in less than 10%.  This distribution
was relatively constant, irrespective of the grade of lesion present in the
index year.  Invasive lesions were significantly more common in the
unscreened women than in those that had been screened.
2. In cervical laser conization for CIN 3, resection margin status is an
important determinant of long term outcome.  The presence of CIN in the
resection margins is a strong indicator of potential treatment failure.
Analyses for HPV status and p53 expression in the cone specimen did not
add predictive information on treatment outcome.
3. The levels of papillomavirus changes cytologically, histologically and on in
situ hybridization were the same in non-progressive and progressive pre-
invasive lesions.  However, detection of HPV by general primer-mediated
PCR was more common in women with lesions progressing to CIN 3 than
in those with non-progressive lesions.
4. DNA could be retrieved and sequenced from up to 75 years old formalin-
fixed, paraffin-embedded tissues.  An automated DNA extraction method
based on magnetic beads was superior to the proteinase-K based
techniques.  HPV was present in the majority of old and new cervical
cancer specimens.  However, only type 16 was detected in the oldest
specimens.
5. The AKT kinase is activated in cervical cancer.  The activation may be
accounted for by PIK3CA amplification, whereas PTEN mutations appear
less important.
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 Errata
The following typographical and grammatical corrections have been made after
submission of the thesis:
Page 10, line 5 of the third paragraph : carcinogenesis,  changed to carcinogenesis .
Page 17, line 1 of the fifth paragraph : p27/KIP1 changed to p27KIP1.
Page 18, line 5 of the last paragraph: p27/KIP1 changed to p27KIP1 and
p21/WAF1/CIP1 changed to p21CIP1.
Page 20, line 6 of the third paragraph:  FAS promoter changed to Fas promoter.
Page 35, line 1 of the third pararaph:  conisation changed to conization.
Page 35, line 4 of the fifth paragraph: in press changed to 449: 141-147.
Page 35, last line: 2006; 118: 1877-1883 changed to 2006; 118: 1877-1883.
